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Reprogramming of human somatic cells uses readily accessible tissue, such as skin or blood, to generate
embryonic-like induced pluripotent stem cells (iPSCs). This procedure has been applied to somatic cells
from patients who are classified into a disease group, thus creating ‘‘disease-specific’’ iPSCs. Here, we
examine the challenges and assumptions in creating a disease model from a single cell of the patient.
Both the kinetics of disease onset and progression as well as the spatial localization of disease in the
patient’s body are challenges to disease modeling. New tools in genetic modification, reprogramming,
biomaterials, and animal models can be used for addressing these challenges.Unleashing the powerful tools of modern cell biology to dissect
mechanisms of human disease requires large quantities of cells
and tissues from specific sets of patients. Human pluripotent
stem cells have the potential to generate all tissues in the body
(Lowry et al., 2008; Park et al., 2008a; Reubinoff et al., 2000;
Takahashi et al., 2007; Thomson et al., 1998; Yu et al., 2007)
and therefore provide researchers in the lab critical access to
patient-derived biomaterial, which constitute the principal input
for such studies of disease. However, there are many technical
challenges in generating and manipulating human pluripotent
cells before they can be thought to be faithful models of specific
diseases. This review will focus on the use of a rising class of
pluripotent cells, ‘‘reprogrammed’’ human induced pluripotent
stem cells (hiPSCs), for modeling human disease pathogenesis.
Modeling human diseases ‘‘in a dish’’ is firmly rooted in human
embryonic stem cell (hESC) biology. In 1998, Thomson and
colleagues derived hESC lines by culturing human blastocysts
in a cocktail of growth factors and supporting mouse feeder cells
(Thomson et al., 1998). These hESC lines were immediately
heralded as foundational for cell replacement therapy and for
modeling human diseases (Gearhart, 1998). Both ‘‘forward’’
and ‘‘reverse’’ genetics approaches have been utilized with
hESCs so that mechanisms of disease could be elucidated. In
the reverse approach, it is possible to test the effects of prede-
fined gene mutations in cells through use of preimplantation
genetic diagnosis (PGD). By performing PGD on embryos,
researchers were able to prospectively identify embryos with
particular genetic disorders and then derive ‘‘disease-specific’’
hESCs for cystic fibrosis (Mateizel et al., 2006; Pickering et al.,
2005), Huntington’s disease (Mateizel et al., 2006), and Fragile
X syndrome (Eiges et al., 2007). Studies using such reverse
genetics approaches are limited because PGD embryos are
only available for a very restricted number of human diseases.
The forward genetics approach starts with a mutagenesis step,
typically using known genomic loci correlated with a specific
disease, followed by the identification of a disease phenotype
in hESCs or their derivatives. In the case of Lesch-Nyhan
disease, the hprt1 gene was mutated in hESCs through homolo-
gous recombination. The resulting hESCs showed an absence in
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‘‘wild-type’’ cells (Urbach et al., 2004). These ‘‘Lesch-Nyhan-
specific’’ hESC lines can be used for further defining the molec-
ular mechanisms of the disease and for screening of drugs that
rescue hprt1 activity. Generating mutant hESC lines as disease
models has been pursued in many laboratories; however,
these studies have faced challenges because of the inefficient
methods to genetically modify hESCs (Giudice and Trounson,
2008). Of course, in the cases for which known disease-associ-
ated genetic loci are unknown, and those for which no obvious
disease phenotype could be screened in hESCs, the forward
genetics approach is also not tenable for disease model
generation.
Concurrent to the development of ‘‘disease-specific’’ hESC
lines, a new technique of deriving human pluripotent stem cells
has rapidly evolved since 2007. hiPSCs were first generated
through viral transduction of four transcription factors into previ-
ously banked human fibroblasts (Lowry et al., 2008; Park et al.,
2008a; Takahashi et al., 2007; Yu et al., 2007). These techniques
have now been applied to blood or skin samples harvested from
patients diagnosed with specific diseases (Dimos et al., 2008;
Ebert et al., 2009; Hotta et al., 2009; Maehr et al., 2009; Park
et al., 2008b; Ye et al., 2009b; Soldner et al., 2009); however,
thus far only a handful of reports have observed a disease
phenotype in vitro (Ebert et al., 2009; Lee et al., 2009; Raya
et al., 2009; Ye et al., 2009b).
Recent work with rodents has tested the developmental
potential of iPSCs and their potential for the treatment of dis-
eases. Differentiation of mouse iPSCs can be directed in vitro
into cardiovascular (Kuzmenkin et al., 2009; Narazaki et al.,
2008; Schenke-Layland et al., 2008), hematopoietic (Hanna
et al., 2007; Schenke-Layland et al., 2008; Xu et al., 2009), neural
(Wernig et al., 2008), and hepatic progenitor cells (Cantz et al.,
2008), and recently, mouse iPSCs passed the most stringent
test of pluripotency by generating full-term adult mice in tetra-
ploid complementation assays (Boland et al., 2009; Kang et al.,
2009; Zhao et al., 2009). Further, mouse iPSCs obtained from
adult fibroblasts can be used for restoration of physiological
function of diseased tissues in vivo, as demonstrated by using
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of sickle cell anemia (Hanna et al., 2007). Also, endothelial cells
derived from mouse iPSCs injected directly into the liver of
irradiated hemophilia A mice extended their survival for more
than 3 months and rescued depleted plasma FVIII levels
(Xu et al., 2009). Finally, functional dopamine neurons could
be generated from reprogrammed mouse fibroblasts, and
transplantation of these neurons, like mESC-derived neurons,
could restore dopamine function when grafted into Parkinsonian
rats (Wernig et al., 2008). These studies establish that
iPSCs have vast potential to generate a variety of functional
cell types and can be used for modifying the course of disease
in rodents.
Although animal models continue to produce key insights into
disease mechanisms, these systems have limitations that could
be potentially overcome by human cellular models of disease.
Many transgenic murine models of congenital and acquired
diseases do not faithfully mirror the respective human patho-
physiology. For example, mice carrying the same genetic defi-
ciencies as Fanconi anemia patients do not develop the sponta-
neous bone marrow failure that is the hallmark of the human
disease (Chen et al., 1996). Differences in tissue composition,
anatomy, and physiology between animals and humans all
may underlie these observations. For instance, the heart rates
of humans and mice differ by 10-fold (Davies and Morris, 1993;
Sothern and Gruber, 1994), and arrhythmias can have very
different consequences in these two species. Another challenge
in using murine disease models can arise from the differences in
colinearity of the human and mouse genomes and the lack of
conservation of gene order. Mice engineered to be trisomic for
those sections of the mouse genome that are orthologous to
the human Down syndrome critical region failed to recapitulate
human cranial abnormalities (Nelson and Gibbs, 2004) or neuro-
degeneration (Reeves et al., 1995) commonly associated with
Down syndrome. Further, only a relatively small subset of age-
regulated gene expression changes is conserved from mouse
to man (Loerch et al., 2008). Lastly, the inbred genetic back-
ground of mice can also influence the phenotype resulting from
the disease-associated mutations. Humans are of mixed genetic
background, and this complexity results in phenotypical varia-
tions of genetically defined diseases. To overcome these draw-
backs of using animals to model human diseases, new hiPSCs
have been generated and explored for disease modeling in
a few cases, as described below.
Current Strategies of Establishing hiPS Cellular
Models of Disease
The establishment of disease models through patient-specific
reprogramming involves two steps: first, derivation of hiPSCs
from somatic cells of a patient and second, differentiating the
hiPSCs into cell types affected by the patient’s disease. Below
we illustrate common principles of this approach with diseases
that have strong genetic etiologies.
Deriving hiPSCs
Typically, cells are harvested from a patient through a biopsy or
blood sample. Harvested samples include adipose adult stem
cells from lipoaspiration (Sun et al., 2009), the CD34+ fraction
of blood samples (Ye et al., 2009b), both fibroblasts and kerati-
nocytes from skin samples (Aasen et al., 2008; Carey et al.,2009), and keratinocytes from plugged hair (Aasen et al.,
2008). In addition, frozen banked tissues or cell lines, such as
fetal brain cortices (Hester et al., 2009) or cord blood (Giorgetti
et al., 2009; Haase et al., 2009), can be reprogrammed.
Choosing which patient donor tissue(s) to reprogram depends
on the type of disease and on the expected pattern of disease
progression. For example, in myeloid proliferative disorders,
a heterozygous JAK2-V617F genotype is observed in 100% of
colony-forming erythroid progenitors in their CD34+ cells, and
these cells were chosen as the source of cells for reprogram-
ming (Ye et al., 2009b). Any contaminating skin or other blood
cells present in the patient’s sample giving rise to an iPSC line
would not contain the JAK2-V617F genotype that correlated
with the disease. Hence, the iPSC lines generated in this study
were genotyped to ensure that they carried the mutation. In
contrast, the genetic mutation correlated with diseases such
as spinal muscular atrophy type I (SMA) is present in all cells,
although the only cell types affected are motor neurons (Ebert
et al., 2009). Therefore, for this class of diseases, readily
accessible skin biopsies can be used as donor cells for hiPSC
line derivation.
Many types of cells are generated during the stochastic
reprogramming process (Chan et al., 2009; Hanna et al., 2009),
including transformed cells or ‘‘intermediates’’ (Chan et al.,
2009; Mikkelsen et al., 2008; Sridharan et al., 2009), and any
newly established cell lines must be extensively tested for pluri-
potency characteristics. For example, oct4 and nanog, endoge-
nous alleles encoding transcription factors specific to ESCs, are
silenced throughmethylation in somatic cells, and demethylation
of these alleles upon reprogramming is a key hallmark of fully
reprogrammed iPSCs (Mikkelsen et al., 2008; Sridharan et al.,
2009; Takahashi et al., 2007; Yu et al., 2007). Differentiation
into all three germ layers with in vitro differentiation is also neces-
sary (Ellis et al., 2009), and using teratoma assays is highly
preferred (Daley et al., 2009). If mutant genes involved in the
pathogenesis of the disease are expressed in the hiPSCs, tran-
scriptional abnormalities in the somatic cells affected in the
patient, such as aberrant splicing or reduced transcript levels,
can be investigated in the established hiPSC lines (Ebert et al.,
2009; Lee et al., 2009).
Differentiating hiPSCs to Functional Cells
Most disease phenotypes are only observed in lineage-com-
mitted or differentiated cells and not in the ESCs or iPSCs.
Thus, pertinent information on the pathogenesis of a disease
may only be obtained from hiPSCs that have been differenti-
ated in vitro to disease-relevant cell types. Differentiation of
hiPSCs into several cell types has already been achieved:
neural progenitors (Chambers et al., 2009), motor neurons
(Dimos et al., 2008; Ebert et al., 2009), dopaminergic neurons
(Soldner et al., 2009), retinal cells (Osakada et al., 2009), hepa-
tocytes (Sullivan et al., 2009), blood cells (Choi et al., 2009;
Ye et al., 2009b), adipocytes (Taura et al., 2009), endothelial
cells (Choi et al., 2009), and fibroblasts (Hockemeyer et al.,
2008; Maherali et al., 2008). During these differentiation proto-
cols that can span multiple weeks, many cell types are gener-
ated, and transcription factor or surface marker expression is
the typical approach used for assaying the developmental
stage of differentiation. The function of these differentiated
cells, thus far, has been assayed in only a few cases: reducedCell Stem Cell 5, December 4, 2009 ª2009 Elsevier Inc. 585
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2009) and erythropoiesis via colony formation assays of hema-
topoietic hiPSC-derivatives (Raya et al., 2009; Ye et al., 2009b).
Functional cellular and biochemical phenotypes, such as tran-
script splicing, were observed upon differentiation into specific
cell types and were ultimately linked to of the known disease
pathology to establish a ‘‘disease model’’ (Ebert et al., 2009;
Lee et al., 2009; Raya et al., 2009; Ye et al., 2009b). Extending
this experimental paradigm to diseases with either unknown or
more complex, multicellular phenotypes or diseases involving
cell types that have yet to be generated in vitro from hESCs
or hiPSCs represents a major current limitation of the
approach.
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Figure 1. Technical Challenges in
Generating Cellular Models of Disease
Recapitulating disease in the laboratory requires
reconstruction of both the kinetics of disease
development and pathology (A) as well as in the
interaction of the principal diseased cell type with
other cell types in the patient’s body (B). As shown
in (A), the dynamics of disease progression in the
patient is likely to take years, whereas phenotypes
developing in vitro in cells differentiated from
patient-specific hiPSCs could be achieved in
days to months. This acceleration could be
achieved through in vitro stress, including expo-
sure of the cells to environmental effects such as
oxidative stress, or by promoting ‘‘ageing’’
in vitro. As shown in (B), cells are typically har-
vested from a patient through a blood sample or
biopsy (shown in this example, although any part
of the body could be used). The harvested sample
is reprogrammed for hiPSC generation, and
a hiPSC line is subsequently differentiated for
production of specific cell types thought to be
affected by the disease. Interaction of the principal
diseased cell type with other cell types within
a tissue or within the diseased patient’s body
may need to be reconstructed in vitro for effective
disease modeling.
Technical Challenges
and Emerging Solutions
As introduced above, although the hiPSC
approach to study pathogenesis has
been attempted for a few monogenic
diseases, disease-modeling strategies
for studying more complex diseases
face even greater challenges. A major
concern to the study of human diseases
in the cell culture dish is that it may be
difficult or not practical to in vitro model
diseases with a long latency such as Alz-
heimer’s or Parkinson’s. In such cases,
the dynamics of disease progression in
the patient is likely to be vastly different
from any phenotype developing in vitro
in cells differentiated from patient-
specific hiPSCs (Figure 1A). One possi-
bility to overcome this challenge would
be attempting to accelerate the appear-
ance of pathological phenotypes in the
cell culture dish by exposing the cells to
environmental effects, such as oxidative stress, that may
contribute to the disease. Issues such as the kinetics of disease
pathology have yet to be addressed with the strategies that have
been published to date. A second major concern for the study of
disease pathogenesis is that it may be difficult or impractical to
model diseases in vitro with a single purified lineage-committed
cell type. In current hiPSC modeling approaches, possible inter-
actions of the cell type that is affected in the patient with other
cell types within a tissue or within the diseased patient’s body
have yet to be systematically reconstructed (Figure 1B), and in
some cases, differentiation protocols required for generating
cell types of interest from pluripotent populations have not
been established. Lastly, diseases with significant epigenetic586 Cell Stem Cell 5, December 4, 2009 ª2009 Elsevier Inc.
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Figure 2. Emerging Tools that May Be Used in Disease Modeling Efforts
Four emerging tools may address technical challenges in modeling diseases in patients through use of hiPSC technology. On the far left is a schematic of the
current approach to disease modeling through reprogramming. New reprogramming strategies utilizing gene excision, DNA transfection, protein transfection,
and small molecules could generate hiPSCs without integrated factors in the genome, termed ‘‘factor-free’’ hiPSCs. Advances in genetic modification allow
for tracking, accentuating, or accelerating pathological phenotypes through introduction of cell-type-specific lineage reporters, as well as disruption, repair,
or overexpression of specific genes (e.g., GFP or disease-gene-of-interest, ‘‘disease-GOI’’). Biomaterials can provide tailored microenvironmental stimuli, which
include neighboring cells, extracellular matrix, soluble factors, and physical forces, in order to reveal pathological mechanisms. Human-animal chimeras with
human blood, neurons, and other tissues have been generated, and these tools could be used for interrogation of the in vivo function of hiPSC derivatives.components may be difficult to study in iPSCs, given that the
reprogramming process is expected to remove any epigenetic
alterations associated with disease phenotypes. Hence, epige-
netic alterations will not persist in the pluripotent iPSCs, an issue
particularly relevant to sporadic and multifactorial disorders
caused by a combination of genetic and environmental factors.
Environmental factors, such as toxic metals and pesticides,
general lifestyle, and dietary habits have been associated with
increased risk in some diseases and may affect the epigenome
(Jaenisch and Bird, 2003). Thus, iPSCs from patients with
sporadic diseases, which are caused predominantly by epige-
netic alterations, may be of little value for mechanistic studies
unless the epigenetic alterations also associate with unidentified
genetic alterations.
Defining a disease-relevant phenotypewill critically depend on
the choice of ‘‘healthy wild-type’’ control cells. A wide range of
control cell lines could be used for comparison with a given
patient-specific hiPSC line, including established hESC lines,
or established hiPSC lines from healthy donors. For establishing
a general model of disease, a panel of lines derived from the
same patient, as well as additional, unrelated patients suffering
from the same disease, should be compared to ensure thatany observations are not specific to a given cell line or to a partic-
ular patient. For example, given the genetic background diversity
that exists between unrelated individuals, the use of control cell
lines derived from healthy siblings may be less likely to result in
background-specific confounding results during experimental
comparisons. In single-gene diseases, genetically rescued
hiPSC lines could represent an ideal isogenic control. In diseases
with somatically acquired mutations, hiPSC lines isolated from
unaffected cell types could be used as controls. For example
in myeloid proliferative disorders that affect the hematopoietic
system, hiPSC lines derived from the skin of the patient would
serve as control lines for studies involving hiPSC lines derived
from the diseased blood.
In the following, we will highlight four technical challenges:
(1) creation of reprogramming factor-free hiPSCs to minimize
or eliminate genetic alterations in the derived iPSC lines;
(2) gene-targeting strategies to generate markers for differentia-
tion and gene corrections; (3) establishing disease-relevant
phenotypes in vitro; and (4) establishing disease-relevant pheno-
types in vivo. In each of these areas, new tools are emerging that
address these challenges and that will make modeling with
hiPSCs more tractable for complex diseases (Figure 2). TheseCell Stem Cell 5, December 4, 2009 ª2009 Elsevier Inc. 587
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Strategy Strengths Potential Obstacles References
Episomal vectors 
Adenoviral vectors
Sendai vectors
Transient transfection
Use of non-integrating vector Possibility of integrated vector subfragments; inefficient
(Fusaki et al., 2009; Gonzalez 
et al., 2009; Okita et al., 2008; 
Stadtfeld et al., 2008; 
Yu et al., 2009)
piggyBac transposon Precise deletion possible Excision may be inefficient and laborious (Kaji et al., 2009; Woltjen et al., 2009)
Lentiviral vectors + Cre Efficient reprogramming and vector deletion
Vector DNA external to the loxP sites remain 
integrated (viral promoters + LTRs)
(Chang et al., 2009; 
Soldner et al., 2009)
Arginine peptide tagged 
proteins No genetic modification Extremely low efficiency
(Kim et al., 2009; 
Zhou et al., 2009)
Small molecules No genetic modification Yet to be demonstrated: still requires at least one factor to be transduced
(Huangfu et al., 2008; Ichida et 
al., 2009; Lyssiotis et al., 2009; 
Shi et al., 2008)
The first direct reprogramming strategies using viral transgenes encoding the transcription factors used in deriving hiPSCs generated hiPSCs with
multiple integrated copies of viral transgenes. These transgenes may be reactivated during disease modeling, and new advances have generated
iPSCs without integrated factors in the genome, termed ‘‘reprogramming factor-free’’ iPSCs.challenges and emerging solutions are described below in the
chronological order probably encountered by researchers in
this field. First, only virus-mediated reprogramming has been
used thus far for generating hiPSCs that display some disease-
specific phenotypes from patients, and because the reprogram-
ming vectors remained integrated in these disease-specific
hiPSCs, it cannot be excluded that residual vector expression
contributed to the observed phenotype. Recently, novel deriva-
tion strategies have been devised to create ‘‘reprogramming
factor-free’’ hiPSCs. Second, gene-targeting interventions
aimed to disrupt, repair, or overexpress genes in hiPSCs are
integral in current strategies to mark and purify the differentiation
stage of hiPSC derivatives and for genetic rescue of diseased
cellular phenotypes. Current prospects for perturbing gene func-
tion in hiPSCs are described. Finally, traditional cell-culture tech-
niques with single differentiated hiPSC types may provide inad-
equate stresses or microenvironments to truly model the onset
and/or progression of disease processes. Both biomaterials
and animal-human chimeras are tools that overcome some of
the limitations of traditional cell culture.
Strategies of Deriving Reprogramming
Factor-free hiPSCs
Residual expression of integrated copies of reprogramming
factors in hiPSCs can affect the gene expression and potentially
biological properties of the resulting iPSC derivatives. In the
most salient example, use of c-Myc as a reprogramming factor
led to high incidence of tumors in chimeras generated with
mouse iPSCs, and it is expected that this oncogene would func-
tion similarly in hiPSCs (Nakagawa et al., 2008). In a more
systematic study through use of Cre-recombinase excisable
viruses, hiPSCs were first derived through viral-vector-mediated
transduction of reprogramming factors and subsequently fol-
lowed by Cre-mediated excision of the vectors (Soldner et al.,
2009). Such factor-free hiPSCs displayed a global gene expres-
sion profile that was more closely related to hESCs than to
genetically identical hiPSCs carrying the transgenes, consistent
with the possibility that basal vector expression may affect the
phenotype of the hiPSCs.
Various new methods have been developed to improve re-
programming technology for generating genetically unmodified588 Cell Stem Cell 5, December 4, 2009 ª2009 Elsevier Inc.or reprogramming ‘‘factor-free’’ hiPSCs (reviewed in O’Malley
et al., 2009). At present, there is no clear optimal method, given
that each approach has strengths and disadvantages (Table 1).
As noted above, the Cre-recombinase method efficiently repro-
grams cells; however, viral elements flanking the loxP sites still
remain after excision. Like the Cre-loxP recombination strategy,
piggyBac transposition has achieved removal of exogenous re-
programming factors from genomic integration sites in iPSCs
(Kaji et al., 2009; Woltjen et al., 2009). The piggyBac transposon
system requires the inverted terminal repeats flanking a trans-
gene and transient expression of the transposase enzyme to
catalyze insertion or excision events. However, the identification
of hiPSCs with minimal-copy vector insertions, integration site
mapping, excision of the reprogramming cassettes, and valida-
tion of factor-free clones can be a laborious process. Noninte-
grating strategies using episomes (Yu et al., 2009), adenoviral
transfection (Stadtfeld et al., 2008), RNA viruses (Fusaki et al.,
2009), or plasmid transfection (Gonzalez et al., 2009; Okita
et al., 2008) are extremely inefficient. Although these approaches
circumvent a few of these obstacles, it is difficult to completely
exclude the possibility that vector subfragments integrated in
the resulting iPSCs. Lastly, protein transfection can generate
genetically unmodified iPSCs, but at exceedingly low efficien-
cies (Kim et al., 2009; Zhou et al., 2009). A variety of small mole-
cules could singly replace reprogramming factors (Huangfu
et al., 2008; Ichida et al., 2009; Lyssiotis et al., 2009; Shi et al.,
2008), but there has yet to be a demonstration of using only small
molecules to reprogram somatic cells.
Genetic Modification of hESCs and hiPSCs
Tracking, accentuating, or accelerating pathological phenotypes
in the lab could greatly benefit from cell-type-specific lineage
reporters, as well as reliable tools to disrupt, repair, or overex-
press genes. First, cell-type-specific lineage reporters would
aid in the enrichment for specific cell types during in vitro differ-
entiation because differentiation techniques for generating
specific somatic cell types affected by disease typically also
produce progenitors and mixed cell cultures, which may inter-
fere with in vitro assays of disease. Indeed, for many cell types
of interest, efficient in vitro generation techniques have yet to
be determined, and thus lineage-tracking tools will likely be
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some human diseases. In addition, such reporters may facilitate
the tracking of diseased cells in cocultures and in chimeric
animals after grafting or transplantation. Further, tools to disrupt,
repair, or overexpress genes could help isolate individual genetic
components in complex disease models. Building up to
a complex disease phenotype from combinations of single
genetic modifications as well as rescuing phenotypes through
gene modification would also be of interest. Lastly, overexpres-
sion of genes that stress or age cells might help to accentuate
phenotypes and/or mimic the induction of disease onset in the
laboratory context. hiPSCs provide an attractive pool of cells
to modify given that they indefinitely self-renew, although most
methods could also be applied to hiPSC derivatives such as
differentiated progenitors that can be easily expanded and
banked.
Tools to achieve expression of transgenes in hESCs or hiPSCs
by random integration of vectors include retroviruses, lentivi-
ruses, bacterial artificial chromosomes, synthetic gene delivery
reagents, and a transposon/transposase system (Giudice and
Trounson, 2008; Placantonakis et al., 2009). Viral gene transfer
into hESCs can be inefficient, given that adeno-associated virus
and adenovirus vectors have been shown to transduce only
0.01%–11% of undifferentiated hESCs (Smith-Arica et al.,
2003). Lentiviral vectors are typically used instead for transgene
expression, given that that these approaches achieve 40%
transduction efficiency in hESCs (Xia et al., 2007). Recently,
synthetic gene delivery approaches have been developed to
rival viral delivery because engineered polymers and cationic
reagents have the ability to condense DNA into particles that
facilitate cellular uptake and endosomal escape (Green et al.,
2008). Finally, piggyBac transposition is host-factor independent
and has recently been demonstrated to be functional in various
hiPSCs (Kaji et al., 2009; Lacoste et al., 2009; Woltjen et al.,
2009). Copy number and integration patterns of the transgenes
are not easily controlled in these strategies.
Targeting specific endogenous genetic loci is a key tech-
nology for studying gene function because this strategy
preserves the flanking genomic context of the target including
important regulatory elements. Since the derivation of the first
hESCs in 1998, only a few reports have described successful
gene targeting by homologous recombination in hESCs (Costa
et al., 2007; Davis et al., 2008; Irion et al., 2007; Zwaka and
Thomson, 2003). These studies used both nonisogenic and
isogenic constructs encoding a drug-selectable cassette intro-
duced into hESCs by electroporation or transfection with
a cationic reagent. Isolation of correctly targeted clones involved
drug selection and screening of clones through PCR or Southern
analysis to check for proper integration of the vectors into the
human genome. Recently, a technique called ‘‘genome editing’’
based on the introduction of DNA double-strand breaks by site-
specific zinc-finger nucleases (ZFNs) to facilitate homologous
recombination (Lombardo et al., 2007) has been used for target-
ing endogenous genes in hESCs and hiPSCs (Hockemeyer et al.,
2009; Zou et al., 2009). A ZFN is generated by fusing the FokI
nuclease domain to a DNA recognition domain composed of
engineered zinc-finger motifs that specify the genomic DNA
binding site for the chimeric protein. Upon binding of two such
fusion proteins at adjacent genomic sites, the nuclease domainsdimerize, become active, and cut the genomic DNA. When
a donor DNA that is homologous to the target on both sides of
the double-strand break is provided, the genomic site can be
repaired by homology-directed repair, thereby allowing the incor-
poration of exogenous sequences placed between the homolo-
gous regions. For ensuring the uniqueness of intended targets
within the human genome, ZFNs containing multiple zinc fingers
need to recognize composite sites of 20–50 bp. ZFNs were used
for engineering several loci in hiPSCs: the disease-related pig-a
locus (Zou et al., 2009); the pitx3 locus, which is not expressed
in hESCs; the oct4 locus for reporting on cell fate; and the
aavs1 locus, used as a ‘‘safe harbor’’ for an inducible transgene
(Hockemeyer et al., 2009). Although vector insertion into these
four loci has been efficient, it is not clear as yet what fraction of
genes can be targeted by this approach.
Toward Tissue Engineering with hiPSC Derivatives
for Generating Disease-Relevant Phenotypes
Cellular functions are influenced not only by cell-autonomous
programs but also by microenvironmental stimuli, which include
neighboring cells, extracellular matrix, soluble factors, and phys-
ical forces. Engineered biomaterials and cocultures may provide
a powerful way to provide a richer context for studying disease
relevant cell-cell interactions (Guilak et al., 2009). These contex-
tual cues are particularly important for modeling non-cell-auton-
omous pathology. In amyotrophic lateral sclerosis (ALS) for
example, cocultures of wild-type, hESC-derived motor neurons
with mutant ALS astrocytes induced motor neuron death (Di
Giorgio et al., 2008; Marchetto et al., 2008).
Whereas full recapitulation of tissue architecture remains
an elusive goal of tissue engineering, smaller functional units
(10–100 mm) have been developed for studying cellular
responses to distinct local stimuli. Bhatia and colleagues used
‘‘soft lithography’’ techniques to create micropatterned cell
clusters, in which 500 mm islands of human hepatic cells are
surrounded by fibroblasts. These micropatterned cell cultures
were then assessed for liver function through gene expression
profiles, metabolism, secretion of liver-specific products, and
susceptibility to hepatotoxins (Khetani and Bhatia, 2008). Pat-
terning approaches can also be applied in three-dimensional
(3D) scaffolds, which have been generated from purified mole-
cules such as collagen and synthetic biomaterials and from
native extracellular matrices from which living cells were previ-
ously extracted (Yamada and Cukierman, 2007). Using hiPSC
derivatives in combination with these and other advances in
biomaterials such as microscale cell patterning and 3D tissue
scaffolds could bridge the gap between traditional cell culture
and animal models.
Generating Disease-Relevant Phenotypes
with Human-Animal Chimeras
It may not be practical to in vitro model diseases with long laten-
cies of onset and/or with complex pathophysiology. Thus, for
some types of disease modeling, in vivo approaches may be
required. Chimeras provide long-term access to complex and
changing environmental context for hiPSCs and are currently
being experimentally explored and optimized. A chimera is an
organism in which tissues of genetically different constitution
coexist as a result of grafting, mutation, or some other process.
Human-animal interspecific chimeras can be generated by
grafting hESC-derived cells into embryos, fetuses, or adultCell Stem Cell 5, December 4, 2009 ª2009 Elsevier Inc. 589
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instances, xenografts created by transplantation of human cells
into immune-privileged sites (e.g., anterior chamber of the eye or
cheek pouch) has been used; however, the most widespread
approaches utilize immunodeficient mice, such as the nude
mouse, severe combined immunodeficiency (SCID) mouse,
and NOG mouse. In this way, animal chimeras engrafted with
human tissues at orthotopic sites have been produced in efforts
to generate ‘‘humanized’’ animals (Friese et al., 2006).
Humanized mouse systems have recently had the most
notable progress with hematopoietic, neural, and hepatic recon-
stitution with human adult stem cells or hESC derivatives
(Behringer, 2007; Shultz et al., 2007). Adult human hematopoi-
etic stem cells have been injected intravenously into irradiated
adult or newborn recipients with significant engraftment (Ishi-
kawa et al., 2005; Shultz et al., 2005). When undifferentiated
hESCs were injected directly into the brain ventricles of fetal
mice, human neurons and glia formed (Muotri et al., 2005),
although it is not clear how differentiated cells were generated
after injection and became incorporated into the brains of the
host animal and why no hESC-derived teratomas formed.
Human adult neural stem cells survive, migrate, and express
differentiation markers for neurons and oligodendrocytes
after long-term engraftment in spinal cord-injured NOD-SCID
mice and in the neonatal, the adult, or the injured rodent brain
(Cummings et al., 2005; Guzman et al., 2007). Lastly, a hepato-
cyte-humanized mouse has been generated for exhibition of
human-type responses in a series of in vivo drug-processing
experiments and in the infection and propagation of hepatic
viruses (Kneteman and Mercer, 2005). Currently, there have
been no reports of using hiPSCs or their derivatives with such
animal models, and these protocols will probably need to be
refined for ensuring more robust engraftment and functionality
of the transplanted human cells.
Outlook
Generating cellular models of disease is a large, long-term
project that will probably take decades in order for the existing
challenges to be addressed adequately for a wide range of
diseases. However, progress has already been attained in
several cases of modeling monogenic, cell-autonomous
diseases with developmental or early-onset pathology (Table 2).
The approach seems particularly tractable for ‘‘orphan-
diseases’’ in which no animal model exists and in which patients
are few and far between. For more complex diseases, we antic-
ipate significant synergy among the four classes of emerging
solutions consisting of reprogramming factor-free hiPSC deriva-
tion, genetic modification of hiPSCs, tissue engineering, and
human-animal chimeras (Figure 2). For example, tissue-engi-
neering approaches could generate splenic capsules from
diabetes-specific hiPSCs that are implanted into humanized
NOD mice to assay functional properties of the hiPSC deriva-
tives. Further, reprogramming-factor-free neural progenitors
from idiopathic Parkinson’s disease-specific hiPSC lines could
be genetically modified to overexpress a mutant form of a-synu-
clein for acceleration of late-onset pathology. Although disease
modeling typically must be well developed before therapeutics
can be identified and tested, several applications utilizing
disease-specific human cell models have already been envi-590 Cell Stem Cell 5, December 4, 2009 ª2009 Elsevier Inc.sioned (Andersson and Lendahl, 2009; Colman and Dreesen,
2009; Daley and Scadden, 2008; Freund and Mummery, 2009;
Rubin, 2008). These applications fall into three major categories:
small-molecule and protein therapeutic discovery, functional
and chemical genomics for elucidating disease mechanisms,
and cell-replacement therapy.
Small-Molecule and Protein Therapeutic Discovery
Recent hiPS cellular disease models already have lead to small-
molecule candidates for treating familial dysautonomia (Lee
et al., 2009) and SMA type I (Ebert et al., 2009). Such cell-based
screening efforts could also be applied to development of mono-
clonal antibodies or other protein therapeutics. Defining appro-
priate in vitro cell function to be used as the readout in thera-
peutic screens will probably be linked to known indicators of
disease amelioration observed in the clinic. In addition, hiPSC
technology could help identify drugs that are only effective
against diseased cells with particular genetic profiles and
advance the detection of off-target drug toxicities. Lastly, this
knowledge may help in narrowing target patient populations
and even reduce the cost of therapeutic testing (Rubin, 2008).
Functional and Chemical Genomics to Elucidate
Disease Mechanisms
In addition to discovering new therapeutics, hiPS cellular
disease models can be used in combination with new tools
designed to systematically perturb cells in vitro in order for eluci-
datingmechanisms of disease. Further, induction of such pertur-
bations in hiPSCs or their derivatives could also inform the
search for improved means of directing differentiation (Xu
et al., 2008). Functional genomics approaches can perturb
102–104 of genes in parallel using libraries of short interfering
hairpins directed against all the genes in the human genome
(Moffat et al., 2006). An alternative approach is the use of small
organic molecules instead of genetic perturbations. This
approach is referred to as ‘‘chemical genomics’’ and is used
for illuminating the molecular mechanisms underlying biological
processes by virtue of the capacity of small molecules to alter
protein activity by binding to their target and inhibiting or acti-
vating their normal functions (Stockwell, 2004). Through use of
libraries of either hairpins or small molecules, mechanisms of
disease can be understood by gain-of-function screens, loss-
of-function screens, or synthetic lethal screens (Grimm, 2004).
Recent studies involving stem cell differentiation (reviewed in
Xu et al., 2008) and reprogramming (Ichida et al., 2009) provide
proof of concept that complex biological mechanisms can be
effectively understood through chemical and functional geno-
mics approaches. hESCs have been treatedwith small-molecule
libraries to elucidate pathways that correlate with hESC self-
renewal and differentiation (Desbordes et al., 2008), and similar
methods will probably also be used with hiPSCs. Further,
chemical and functional genomics screening has already identi-
fied genes and pathways important in enhancing hiPSC forma-
tion—TGF-b and MEK signaling with small molecules (Ichida
et al., 2009) and p53 with smaller-scale siRNA knockdowns
(Zhao et al., 2008). Utilizing similar approaches with patient-
specific hiPSCs could help elucidate unknown mechanisms of
disease.
Cell Transplantation into Patients
Given the limitations of any in vitro or animal model of disease, it
may be that some insight into human disease will only come after
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Disease 
Categories 
Motivating Factors Potential Complicating Factors Existing hiPSC 
Lines  
  Multifactorial genetics 
Human-
specific 
pathology 
Molecular & 
histopathology  
well-
characterized 
Other 
Non-cell 
autonomous 
pathology 
Environmental 
stresses  Other   
Fa
m
ilia
l 
+ / ? + + 
Mendelian 
genetics in many 
cases; Early 
onset in some 
cases 
 + ? 
Network 
dysfunction 
likely important 
Dysautonomia (Lee 
et al., 2009); SMA 
type 1 (Ebert et al., 
2009); Huntington's 
disease (Park et al., 
2008b); ALS (Dimos 
et al., 2008) 
N
eu
ro
de
ge
ne
ra
tiv
e 
Sp
or
ad
ic 
+ + + 
Cellular 
pathology well-
defined  + + 
Network 
dysfunction 
likely important 
Parkinson's disease 
(Park et al., 2008b; 
Soldner et al., 2009) 
N
eu
ro
-
de
ve
lo
pm
en
ta
l 
+ / ? + / ? + 
Well-defined 
genetic lesions 
in many cases 
+ ? 
Complex 
phenotypes 
involving many 
parts of the 
body; Network 
dysfunction 
likely important 
Rett syndrome  
(Hotta et al., 2009);  
Down syndrome 
(Park et al., 2008b) 
N
eu
ro
lo
gy
 
N
eu
ro
be
ha
vi
or
al
 /  
   
  
Ps
yc
ho
lo
gi
ca
l 
+ +  ? 
Opportunity to 
define cellular 
pathology 
+ / ? + 
Network 
dysfunction 
likely important 
None published 
H
em
at
ol
og
y 
/ O
nc
ol
og
y 
+ / ? + / ? + 
Well-defined 
genetic lesions 
in some cases; 
Opportunity to 
distinguish 
epigenetic & 
genetic 
components; 
Correct known 
genetic defects 
readily via bone-
marrow 
manipulation 
 ? + / ? 
Assaying 
function of 
hematopoietic 
derivatives; 
iPSC state may 
erase important 
epigenetic 
alterations 
-thalassemia  
(Ye et al., 2009a);  
Fanconi anemia 
(Raya et al., 2009); 
Myeloproliferative 
disorders  
(Ye et al., 2009b) 
En
do
cr
in
ol
og
y 
+ / ? ? + / ? 
Well-defined 
cellular 
pathology; Well-
defined genetic 
lesions in some 
cases 
+ / ? + / ?  Autoimmune response may 
be important  
Juvenile diabetes 
mellitus  
(Maehr et al., 2009; 
Park et al., 2008b) 
 
In
fe
ct
io
us
 
di
se
as
es
 
+ + / ?  + / ? 
Amenable to 
reverse genetics 
to look for host 
susceptibility 
factors 
 ?  ? 
Susceptibility 
could rely on 
specific 
aspects of 
physiology 
None published 
+, significant motivating or complicating factor in nearly all cases; ?, unknown whether factor is significant in nearly all cases;  
+ / ?, significant factor in some cases and unknown factor in the remaining cases.  
Table is illustrative of different challenges facing efforts to model several types of disease and is not an exhaustive list of hiPSC models. For infectious
diseases, a humanized mouse model with hiPSC-derived cells could be challenged with an infectious disease to explore human host factors that
confer resistance. Three motivating factors are highlighted. First, the genetics of the disease may be an important factor. On the one hand, if disease
etiology is expected to involve many genetic lesions across the human genome, the hiPSC technology can provide a cell line that contains the appro-
priate disease-relevant combinations of these lesions. On the other hand, clear Mendelian genetics enables one to be certain that the genetic lesion is
captured in the hiPSC-derived cells. Second, if animal models could not reasonably be expected to recapitulate disease pathology or phenotype (most
particularly for psychiatric diseases), hiPSC-derived cells may be the best option for studying the cellular changes involved in a particular disease.
Third, where there is well-characterized pathology in human diseases, phenotypes observed in hiPSC derivatives can be more easily related to those
seen in patients. Lastly, two potential complicating factors are emphasized. Non-cell-autonomous pathology will probably be difficult to model with
differentiated hiPSC cell types, and environmental stresses may be difficult to recapitulate experimentally. If disease-specific hiPSCs have been
derived from particular patient groups, the references are listed on the right-most column.Cell Stem Cell 5, December 4, 2009 ª2009 Elsevier Inc. 591
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Transplantation of hiPSC derivatives into focal, diseased lesions
would probably be the first application of cell replacement
therapy, although it is currently unclear whether fully differenti-
ated cells or progenitor or stem cells would more easily reconsti-
tute the tissues at the site(s) of disease. Challenges in using
cell therapy with hiPSCs have been recently reviewed (Colman
and Dreesen, 2009; Daley and Scadden, 2008; Freund and
Mummery, 2009; Kiuru et al., 2009). In addition to the modeling
considerations described herein, for the use of stem cell deriva-
tives in human therapy, it will be particularly important to monitor
cell karyotype to detect chromosomal abnormalities that could
arise during prolonged cell culture (Spits et al., 2008). Karyotypic
changes have been repeatedly reported for hESCs expanded in
culture and might also be expected for hiPSCs, given that these
could cause tumorigenicity in addition to teratoma formation
after transplantation of derivatives into patients. Lastly, factor-
free reprogramming in fully defined, feeder-free culture condi-
tions will probably be a regulatory requirement for this class of
cell-based therapeutics.
Closing Comments
Disease models utilizing patient-specific hiPSCs will probably
generate a wealth of information and data that could be
combined with genetic analyses of disease. The combination of
genetic and hiPSC trait information may allow early and more
accurate prediction and diagnosis of disease and disease
progression. Further, the redefinition of disease subtypes
through such disease modeling is likely to provide many exam-
ples of differential response to therapy, and understanding of
individual responses to drugs will have implications for their use
and development by the pharmaceutical industry. Such work is
envisioned, in one example, to proceed in collaboration with
the ‘‘PersonalGenomesProject.’’ Lastly, this researchwill require
new social arrangements among patients, doctors, and bench
researchers, and these arrangements may challenge existing
institutional and state policies in regards to property, privacy,
and human dignity involving such novel human cellular material
and modeling data. These societal challenges are outside of
the scope of this article, but will probably also guide the develop-
ment of this research area insofar as it is conceived as an effort to
respond directly to clinical need. Therefore, research at the
bench is likely to be structured to take into account the legal,
ethical, regulatory, and economic environment that mediates
basic research from clinical application. It will be important to
maintain awareness of these extrinsic factors as this research
area develops in order to produce the most robust science while
also responding to the urgency of developing new clinical tools.
By framing disease at the cellular level with human embryonic-
like material, in contrast to the genetic level or the model-
organism level, researchers in this field face unique technical
challenges. Emerging solutions involve several areas of bio-
medical research and are likely to be used for producing new
molecular understanding of a wide range of diseases.
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